GlassScriptPhysician profile
Suniti A Warey
NPI 1427397983
$2,159.27
in general payments reported to CMS, 2019-2025
14 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $313 · 2023: $518 · 2024: $616 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $471.70 | 2022-2025 | Zepbound, Olumiant |
| Genzyme Corporation | $358.96 | 2023-2024 | |
| Galderma Laboratories, L.P. | $271.72 | 2025 | Nemluvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.64 | 2023 | Lifevest |
| Viiv Healthcare Company | $122.39 | 2025 | Apretude |
| Glaxosmithkline, LLC. | $118.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $115.39 | 2023 | Sotyktu |
| Gilead Sciences, INC. | $108.39 | 2023 | Epclusa |
| Vertex Pharmaceuticals Incorporated | $104.00 | 2024 | |
| Pfizer INC. | $99.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.59 | 2022 | |
| Cochlear Americas | $76.02 | 2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Neurocrine Biosciences, INC. | $62.63 | 2024 | Ingrezza |
| Smith+Nephew, INC. | $23.12 | 2024 | Tula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suniti Warey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.